Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

Investors in Merck & Co Inc (Symbol: MRK) saw new options begin trading today, for the August 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

One such company is Merck & Co Inc (Symbol: MRK), which saw buying by Director Inge G. Thulin. Back on February 6, Thulin invested $249,999.98 into 2,833 shares of MRK, for a cost per share of $88.25.

Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is r ...

Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.56 billion and $1.72 per ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

**NM signifies a non meaningful value. A dash signifies the data is not available.